查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1858140

克拉伯氏症治療市場按治療類型、給藥途徑、治療場所、通路、最終用戶和患者年齡層分類－2025-2032年全球預測

Krabbe Disease Treatment Market by Therapy Type, Administration Route, Treatment Setting, Distribution Channel, End User, Patient Age Group - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，克拉伯氏症治療市場規模將達到 30.9 億美元，複合年成長率為 6.77%。

關鍵市場統計數據
基準年 2024 18.3億美元
預計年份：2025年 19.5億美元
預測年份 2032 30.9億美元
複合年成長率 (%) 6.77%

權威的臨床和商業介紹，涵蓋克拉伯病的生物學、當前治療途徑、診斷進展和不斷發展的治療前沿。

克拉伯氏症是一種罕見的進行性性溶小體貯積症，由半乳糖腦苷脂酶缺乏引起，導致廣泛的去髓鞘化和嚴重的神經退化退化。臨床上，該疾病從快速進展的兒童型到進展較慢的晚髮型不等，早期診斷是決定臨床預後的最重要因素之一。目前的治療策略著重於支持性治療和症狀治療，但造血幹細胞移植已被證明對部分患者早期應用有效。儘管治療方法取得了這些進展，但仍存在一些未被滿足的需求，包括持久的疾病修飾、安全地將矯正基因和酵素導入中樞神經系統，以及支持長期後續觀察的可擴展治療模式。

整合關鍵的技術、診斷、監管和支付方方面的變革，重新定義克拉伯氏症治療的臨床開發和商業化。

克拉伯氏症治療格局正經歷著從實驗室創新到臨床應用等一系列相互關聯的變化。載體設計方面取得了顯著進展。嗜神經腺結合病毒血清型和工程化衣殼的出現，使得藥物能夠更有效地遞送至中樞神經系統；同時，慢病毒平台和表達盒安全性的提升，也增強了體外造血幹細胞基因治療的可行性。與這些技術進步相伴而生的是，給藥途徑的改進也取得了進展，人們重新關注鞘內和腦室內給藥，以最大限度地提高藥物在中樞神經系統的暴露量，並減少外周脫靶效應。

基於證據的評估，分析美國關稅政策的變化將如何影響克拉伯氏症治療供應鏈、生產經濟、臨床計畫和取得途徑

影響貿易和關稅的政策變化會對生技藥品和罕見疾病先進療法的研發、生產和供應產生連鎖反應。進口原料、專用試劑以及病毒載體生產和細胞處理所需資本設備的關稅增加，可能會提高上游生產成本，並影響工廠位置決策。對於臨床項目而言，關稅導致的低溫運輸耗材、給藥裝置和一次性生物反應器組件成本上漲，可能會延長採購週期，並需要重新評估供應商合格策略，以確保臨床實驗按時完成並符合監管要求。

透過對治療方法、給藥途徑、治療環境、分銷管道、最終用戶和患者人口統計特徵進行細緻的細分，可以製定切實可行的開發和准入策略。

在異質性極強的克拉伯氏症整體情況，以細分市場主導的策略對於進行臨床開發和商業化工作至關重要。治療方法方法包括酵素替代療法、基因療法、造血幹細胞移植和支持性治療。在基因治療領域，不同的載體，例如腺相關病毒（AAV）和慢病毒平台，對應不同的臨床和商業策略。 AAV介導的基因治療方案分為AAV2和AAV9血清型，主要採用體內中樞神經系統遞送方式；而慢病毒策略則根據第二代和第三代構建體進行區分，通常支持體外造血幹細胞的修復，並具有不同的安全性和生產特性。造血幹細胞移植分為異體移植和自體移植，每種移植方式都需要獨特的供體取得、預處理方案和移植後監測。

從區域策略觀點出發，協調美洲、中東和非洲以及亞太地區的臨床試驗設計、生產方案和市場准入舉措。

地理因素影響克拉伯氏症治療的臨床重點和營運需求。在美洲，強大的兒童神經病學和移植專家團隊以及先進的新生兒篩檢項目，使得早期療育臨床試驗和整合式診療路徑的建立成為可能。該地區的醫療保險機構通常專注於基於價值的合約和基於結果的報銷機制，以獎勵收集持久功能性療效數據和建立長期追蹤登記系統。

提供可操作的公司和生態系統情報，重點關注研發公司、合約研發生產機構 (CDMO)、臨床網路、專業服務供應商和夥伴關係模式在推動克拉伯病計畫成功中所發揮的作用。

克拉伯病生態系統涵蓋創新者、臨床網路、生產機構和專業服務供應商，他們的互動決定著研發進度和患者獲取治療的機會。生物技術和基因治療開發人員正透過載體設計、基因表現最佳化以及細胞療法中預處理方案的改進，推動轉化創新。同時，受託製造廠商也不斷提升自身能力，以支持病毒載體生產、細胞處理和品質體系，從而滿足持久性基因表現療法的嚴格監管要求。

為贊助商、醫療服務提供者和支付者提供切實可行的優先建議，以加速克拉伯氏症治療藥物的研發，確保供應穩定，並保障患者長期獲得治療。

產業領導者應採取果斷措施，將科學前景轉化為永續的臨床和商業性成果。首先，將新生兒篩檢途徑和早期診斷演算法納入臨床試驗招募和計畫規劃，以最佳化治療效果並縮短無症狀嬰兒的治療療程。其次，制定靈活的生產策略，結合專業技術和區域能力，在維持成本效益和合規性的同時，確保穩定的供應。第三，優先進行給藥途徑研究，比較鞘內、腦室內和靜脈給藥方式，並採用統一的療效評估指標，為臨床最佳實踐和與支付方的討論提供依據。

我們透明的多來源調查方法結合了臨床文獻、監管研究、專家訪談和供應鏈分析，以得出策略性結論和建議。

這些研究成果綜合了多方面的證據，以確保得出穩健且基於臨床的結論。一級資訊來源包括對載體工程技術白皮書、生技藥品監管機構的生產指南以及關於供應鏈物流和低溫運輸物流的開放原始碼報告的分析。此外，我們也訪問了臨床醫生、臨床實驗研究人員、生產負責人和負責人，從實踐觀點探討了營運障礙和推廣應用的促進因素。

簡潔扼要、具有前瞻性的結論，綜合分析了克拉伯病臨床機會、營運風險和戰略重點，這些對於將創新轉化為持續的患者可及性至關重要。

克拉伯氏症的治療策略呈現出策略性機遇，這得益於載體技術的進步、新生兒篩檢的擴大以及罕見疾病監管法規的日趨完善。要讓患者獲得持續的治療獲益，僅靠科學突破是不夠的。它還需要在以下方面進行協調投資：提升生產能力、設計務實的臨床試驗以早期療育，以及製定符合支付方利益的證據策略，量化長期功能獲益。給藥途徑、醫療機構和分銷模式之間的相互作用將決定治療的實際實施方式，而以細分市場為重點的專案規劃將提高營運和商業性成功的幾率。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 一種用於克拉伯氏症患者標靶恢復 GALC 酶活性的新型基因編輯和 AAV 載體方法
  • 一種創新的小分子Chaperone，旨在增強患者體內GALC酶的穩定性和功能。
  • 新生兒篩檢技術的進步有助於早期發現克拉伯氏症並改善其預後
  • 擴大學術機構與生物技術公司之間的合作，以加速克拉伯氏症治療方法的發現和臨床試驗。
  • 患者權益倡導團體更多地參與到籌款和提高公眾意識的工作中，以推進克拉伯病的研究和治療。

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

克拉伯氏症治療市場依治療類型分類

  • 酵素替代療法
  • 基因治療
    • AAV載體
      • AAV2
      • AAV9
    • 慢病毒載體
      • 第二代
      • 第三代
  • 造血幹細胞移植
    • 同種異體移植
    • 自體移植
  • 支持性護理

9. 按給藥途徑分類的克拉伯氏症治療市場

  • 鞘內注射
    • 腦室內
    • 腰椎穿刺
  • 靜脈
    • 中央靜脈導管
    • 周邊靜脈

第10章 克拉伯氏症治療市場：依治療場所分類

  • 住院病人
    • 專科診所
    • 三級醫院
  • 門診病人
    • 門診部
    • 居家照護

第11章 克拉伯氏症治療市場依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房
  • 專科藥房
    • 獨立專科藥房
    • 管理式專科藥房

第12章 依最終用戶分類的克拉伯氏症治療市場

  • 診所
    • 綜合診所
    • 專科診所
  • 居家照護提供者
    • 許可機構
    • 病人家
  • 醫院
    • 兒童醫院
    • 綜合醫院

按患者年齡層分類的克拉伯氏症治療市場

  • 嬰兒期
    • 症狀
  • 延遲
    • 青年
    • 成人
  • 新生
    • 早期診斷
    • 症狀前

克拉伯氏症治療市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 克拉伯氏症治療市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 各國克拉伯病治療市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Passage Bio, Inc.
    • Bluebird Bio, Inc.
    • Genethon
    • Forge Biologics
    • Polaryx Therapeutics
Product Code: MRR-C002B1C9976C

The Krabbe Disease Treatment Market is projected to grow by USD 3.09 billion at a CAGR of 6.77% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.83 billion
Estimated Year [2025] USD 1.95 billion
Forecast Year [2032] USD 3.09 billion
CAGR (%) 6.77%

An authoritative clinical and commercial introduction that frames Krabbe disease biology, current care pathways, diagnostic advances, and the evolving therapeutic frontier

Krabbe disease is a rare, progressive lysosomal storage disorder caused by deficiency of galactocerebrosidase, leading to widespread demyelination and severe neurodegeneration. Clinically heterogeneous presentations range from rapidly progressive infantile forms to more indolent late-onset phenotypes, and early diagnosis is among the most important determinants of clinical outcomes. Current care pathways emphasize supportive management and symptomatic interventions, while hematopoietic stem cell transplantation has demonstrated benefit when applied early in select patients. Despite these therapeutic advances, unmet needs persist in durable disease modification, safe delivery of corrective genes or enzymes to the central nervous system, and scalable models of care that support long-term follow-up.

Over the past decade, rapid advances in molecular diagnostics, newborn screening, and vector engineering have coalesced to create an inflection point for therapeutic innovation in Krabbe disease. Translational programs are increasingly focusing on neurotropic delivery, immune modulation, and ex vivo stem cell gene correction to achieve sustained expression of galactocerebrosidase in target tissues. Concurrently, regulatory pathways for rare disease interventions are maturing, with greater emphasis on natural history datasets, surrogate endpoints, and patient-reported outcomes. These converging forces are reshaping clinical development priorities, payer dialogues, and infrastructure requirements for advanced therapies, and they underline the importance of aligning clinical trial design, manufacturing scale-up, and commercialization planning from the earliest stages of program development.

A synthesis of the pivotal technology, diagnostic, regulatory, and payer shifts that are redefining clinical development and commercialization for Krabbe disease therapies

The therapeutic landscape for Krabbe disease is being transformed by several interlocking shifts that extend from bench innovation through to care delivery. Vector design has progressed substantially: adeno-associated virus serotypes with enhanced neurotropism and engineered capsids are enabling more effective central nervous system transduction, while advances in lentiviral platform safety and expression cassettes have strengthened the viability of ex vivo hematopoietic stem cell gene therapies. These technology improvements are paralleled by procedural refinements in administration routes, with renewed focus on intrathecal and intracerebroventricular delivery to maximize CNS exposure and reduce peripheral off-target effects.

Concurrently, adoption of newborn screening is accelerating early identification of affected infants, shifting the clinical imperative toward pre-symptomatic intervention and reshaping enrollment strategies for interventional studies. This trend has important implications for clinical trial design, as outcome measures and time horizons must be tailored to reflect early therapeutic windows. Manufacturing and supply chain innovations are also altering program economics: modular and decentralized manufacturing approaches, improvements in vector yield and potency, and stronger cold-chain logistics are easing some historical bottlenecks. Finally, payer engagement is evolving; value frameworks are expanding to incorporate long-term functional outcomes and caregiver burden, and risk-sharing constructs are increasingly employed to align payment with durable clinical benefit. Together, these shifts are accelerating translational momentum while introducing new operational complexities that sponsors and health systems must navigate proactively.

An evidence-based assessment of how changes in United States tariff policy reverberate through supply chains, manufacturing economics, clinical programs, and access pathways for Krabbe disease therapies

Policy changes affecting trade and tariffs can have ripple effects across the development, manufacture, and delivery of biologics and advanced therapies for rare diseases. Increased duties on imported raw materials, specialized reagents, and capital equipment used in viral vector production and cell processing can raise upstream production costs and influence facility siting decisions. For clinical programs, tariffs that elevate the cost of cold-chain consumables, drug-delivery devices, or single-use bioreactor components can lengthen procurement cycles and require re-evaluation of supplier qualification strategies to maintain trial timelines and regulatory compliance.

Beyond direct input costs, tariff-related friction impacts logistics and the resiliency of global supply chains. Higher cross-border costs and administrative burdens can prompt sponsors to favor domestic suppliers where feasible, increasing demand for onshore contract manufacturing capacity and incentivizing investment in decentralized production capabilities. For therapies that require international clinical enrollment, tariffs that affect ancillary supplies or imported comparator products can complicate cross-border trial operations and escalate per-patient trial expenditures. Payers and health systems may confront compression of budgetary headroom as higher acquisition costs compete with other priorities, intensifying negotiations over reimbursement and risk-sharing agreements.

Mitigation strategies are important to preserve access and program feasibility. Sponsors can invest in diversified supplier networks, qualify alternate reagent sources, and build regional manufacturing hubs to reduce exposure to single-point import risks. Strategic inventory planning, long-term supplier contracts, and collaborative procurement consortia can smooth volatility. Regulatory teams should incorporate tariff sensitivity into early-stage economic modeling and supply chain risk assessments to ensure that clinical and commercial launch plans remain executable under a range of trade-policy scenarios. Ultimately, the cumulative impact of tariff changes is not limited to unit cost; it influences talent allocation, facility investment, and partnership strategies that determine whether innovative Krabbe disease therapies can be delivered reliably to patients.

Granular segmentation insights that map therapy modalities, administration pathways, care settings, distribution channels, end users, and patient age cohorts to pragmatic development and access strategies

Segmentation-driven strategy is essential for targeting clinical development and commercialization efforts across the heterogeneous Krabbe disease landscape. When therapies are classified by type, the field spans enzyme replacement therapy, gene therapy, hematopoietic stem cell transplantation, and supportive therapy. Within gene therapy, distinct vectors such as AAV and lentiviral platforms warrant separate clinical and commercialization strategies because AAV-mediated programs-delegated into AAV2 and AAV9 serotypes-favor in vivo CNS transduction approaches, whereas lentiviral strategies-distinguished by second generation and third generation constructs-often underpin ex vivo correction of hematopoietic stem cells and different safety and manufacturing profiles. Hematopoietic stem cell transplantation itself divides into allogeneic and autologous modalities, each with unique donor sourcing, conditioning regimens, and post-procedure monitoring requirements.

Administration route further segments clinical practice and operational planning, splitting programs into intrathecal and intravenous approaches. Intrathecal delivery, encompassing intracerebroventricular administration and lumbar puncture techniques, enables targeted CNS exposure but requires specialized procedural expertise and infrastructure. Intravenous delivery, implemented via central venous catheter or peripheral vein access, may offer broader systemic distribution and easier outpatient administration in certain contexts, yet presents different immunological and biodistribution considerations. Treatment setting stratification illuminates care pathways, separating inpatient and outpatient environments; inpatient care delivered through specialty clinics and tertiary hospitals supports intensive conditioning and monitoring, whereas outpatient pathways in ambulatory clinics and home care settings can reduce caregiver burden and improve continuity for long-term follow-up.

Distribution channel choices influence patient access and specialty dispensing capabilities. Hospital pharmacy, online pharmacy, retail pharmacy, and specialty pharmacy models each present distinct logistics, reimbursement interfaces, and patient support frameworks, with specialty pharmacies further differentiated between independent specialty pharmacies and managed specialty pharmacies that integrate adherence and distribution analytics. End user segmentation-encompassing clinics, home care providers, and hospitals-adds another layer, as clinics can be organized as multispecialty or specialty clinics, home care providers may operate as licensed nursing agencies or support care directly in the patient's home, and hospitals may be children's hospitals or general hospitals with varying levels of pediatric expertise. Patient age group segmentation is equally consequential for clinical design and market access planning: neonatal populations require workflows oriented to early diagnosis and pre-symptomatic intervention; infantile cohorts are typically symptomatic and demand rapid initiation of therapy; and late-onset patients include adolescent and adult subgroups with different progression rates and outcome priorities. Integrating these segmentation axes enables sponsors to align trial inclusion criteria, caregiver support services, delivery model investments, and reimbursement strategies to the clinical realities of each patient subset.

Regional strategic perspectives that align clinical trial design, manufacturing choices, and market access initiatives across the Americas, Europe Middle East & Africa, and Asia-Pacific

Geographic dynamics shape both clinical priorities and operational requirements for Krabbe disease interventions. In the Americas, robust centers of pediatric neurology and transplant expertise combined with progressive newborn screening programs have driven an emphasis on early-intervention clinical trials and the development of integrated care pathways. Health payer engagement in this region often centers on value-based contracting and outcomes-based reimbursement structures, which incentivize data collection for durable functional outcomes and long-term follow-up registries.

Europe, the Middle East & Africa presents a diverse mosaic of regulatory environments and healthcare delivery models. Several European markets have well-established rare disease frameworks and pan-national networks that facilitate multicenter trials, yet heterogeneity in reimbursement pathways and regional drug approval timelines requires nuanced market access planning. Healthcare systems across this region vary in their capacity to provide advanced inpatient services, and partnerships with specialist centers are frequently essential to ensure consistent access to complex therapies and post-treatment monitoring.

Asia-Pacific is characterized by rapidly expanding clinical research capacity, increasing newborn screening initiatives in select jurisdictions, and growing local manufacturing capabilities. Diverse regulatory pathways and policy priorities in the region create both opportunities for accelerated trial enrollment and challenges for synchronized market entry. Investments in regional manufacturing and supply-chain partnerships can reduce logistical complexity and support more predictable product availability, while collaboration with local clinical networks helps tailor educational and support programs for families navigating rare disease care.

Actionable corporate and ecosystem intelligence highlighting the roles of developers, CDMOs, clinical networks, specialty service providers, and partnership models driving Krabbe disease program success

The Krabbe disease ecosystem encompasses a constellation of innovators, clinical networks, manufacturing organizations, and specialty service providers whose interactions determine development velocity and patient access. Biotech and gene therapy developers are driving translational innovation by advancing vector design, optimizing transgene expression, and refining conditioning regimens for cell-based approaches. At the same time, contract development and manufacturing organizations are evolving capabilities to support viral vector production, cell processing, and quality systems that meet stringent regulatory expectations for durable gene-expression therapies.

Clinical and academic centers provide indispensable natural history datasets and trial sites, and their collaboration with industry sponsors accelerates protocol optimization and endpoint selection. Specialty pharmacies, patient support organizations, and home-care providers contribute to the post-authorization ecosystem through coordinated distribution, adherence management, and long-term outcomes monitoring. Strategic partnerships-whether between developers and CDMOs, clinical consortia and payers, or distribution partners and hospitals-are increasingly prevalent as stakeholders seek to de-risk scaling and ensure continuity of care. Observing how these actors align incentives, share data, and negotiate risk-sharing and licensing arrangements offers the clearest signal of which programs will be operationally ready to transition from clinical development to widespread patient access.

Practical, prioritized recommendations for sponsors, care providers, and payers to accelerate development, ensure supply resilience, and secure durable patient access for Krabbe disease therapies

Industry leaders should take decisive steps to translate scientific promise into sustainable clinical and commercial outcomes. First, integrate newborn screening pathways and early-diagnosis algorithms into trial recruitment and program planning to optimize therapeutic impact and shorten time-to-treatment for pre-symptomatic infants. Second, build flexible manufacturing strategies that combine centralized expertise with regional capacity, enabling supply security while preserving cost efficiencies and regulatory compliance. Third, prioritize administration-route studies that compare intrathecal, intracerebroventricular, and intravenous approaches with harmonized outcome measures to inform both clinical best practice and payer discussions.

Fourth, develop comprehensive payer engagement plans that emphasize real-world evidence collection, long-term functional outcomes, and caregiver-centered endpoints; design risk-sharing constructs that align payment with sustained clinical benefit. Fifth, invest in cross-functional partnerships: collaborate with specialty pharmacies, home-care providers, and tertiary referral centers to design patient-centric delivery models that minimize caregiver burden and maximize adherence. Sixth, elevate pharmacovigilance and long-term registries early in program design to capture durability, safety, and quality-of-life metrics essential for regulatory and reimbursement dialogues. Taken together, these actions create a roadmap to reduce implementation risk, accelerate access, and ensure that scientific advances translate into meaningful improvements for patients and families affected by Krabbe disease.

A transparent, multi-source research methodology combining clinical literature, regulatory review, expert interviews, and supply-chain analysis to underpin strategic conclusions and recommendations

The research behind these insights combined multiple evidence streams to ensure robust, clinically grounded conclusions. Primary sources included peer-reviewed clinical literature, regulatory guidance documents, and clinical-trial registry reviews to synthesize efficacy, safety, and endpoint trends. Secondary research encompassed analysis of technical white papers on vector engineering, manufacturing guidance from biologics authorities, and open-source reports on supply-chain logistics and cold-chain requirements. Expert interviews with clinicians, trial investigators, manufacturing leaders, and payers provided practical perspectives on operational hurdles and adoption drivers.

Analytical approaches integrated comparative technology appraisal, segmentation mapping, and scenario analysis to evaluate strategic implications across development and commercialization pathways. Careful attention was paid to clinical heterogeneity, differences in healthcare infrastructure across regions, and procedural nuances tied to administration routes. Wherever possible, conclusions were validated against multiple independent sources and cross-checked with expert opinion to ensure relevance and applicability to stakeholders engaged in Krabbe disease program planning.

A concise and forward-looking conclusion that synthesizes clinical opportunity, operational risks, and the strategic priorities essential for converting innovation into sustained patient access for Krabbe disease

Krabbe disease occupies a moment of strategic opportunity driven by advances in vector technology, expanding newborn screening, and maturing regulatory frameworks for rare diseases. Realizing durable therapeutic impact for affected patients will require more than scientific breakthroughs; it demands coordinated investments in manufacturing resilience, pragmatic clinical trial design that targets early-intervention windows, and payer-aligned evidence strategies that quantify long-term functional benefit. The interplay between administration routes, care settings, and distribution models will determine how therapies are delivered in practice, and segmentation-driven program planning improves the odds of operational and commercial success.

Risks remain, including supply-chain fragility in the face of trade-policy changes, the complexity of scaling manufacturing for viral vectors and cell therapies, and the need to standardize outcomes that matter to patients and payers. Nonetheless, sponsors who act early to secure supply chains, engage stakeholders across clinical and payer communities, and invest in long-term evidence generation will be best positioned to convert scientific progress into sustainable patient impact. The path forward is collaborative: aligning clinical, manufacturing, regulatory, and commercial functions around patient-centered objectives will be the defining factor in whether promising interventions reach the families who need them.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Emerging gene editing and AAV vector approaches for targeted GALC enzyme restoration in Krabbe disease patients
  • 5.2. Innovative small molecule chaperones designed to enhance GALC enzyme stability and function in patients
  • 5.3. Advancements in newborn screening technologies for early detection of Krabbe disease and improved outcomes
  • 5.4. Growing collaborations between academic institutions and biotech firms to accelerate Krabbe disease therapeutic discovery and trials
  • 5.5. Increased patient advocacy group involvement driving funding and awareness for Krabbe disease research and treatment access

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Krabbe Disease Treatment Market, by Therapy Type

  • 8.1. Enzyme Replacement Therapy
  • 8.2. Gene Therapy
    • 8.2.1. AAV Vector
      • 8.2.1.1. AAV2
      • 8.2.1.2. AAV9
    • 8.2.2. Lentiviral Vector
      • 8.2.2.1. Second Generation
      • 8.2.2.2. Third Generation
  • 8.3. Hematopoietic Stem Cell Transplantation
    • 8.3.1. Allogeneic
    • 8.3.2. Autologous
  • 8.4. Supportive Therapy

9. Krabbe Disease Treatment Market, by Administration Route

  • 9.1. Intrathecal
    • 9.1.1. Intracerebroventricular
    • 9.1.2. Lumbar Puncture
  • 9.2. Intravenous
    • 9.2.1. Central Venous Catheter
    • 9.2.2. Peripheral Vein

10. Krabbe Disease Treatment Market, by Treatment Setting

  • 10.1. Inpatient
    • 10.1.1. Specialty Clinics
    • 10.1.2. Tertiary Hospitals
  • 10.2. Outpatient
    • 10.2.1. Ambulatory Clinics
    • 10.2.2. Home Care

11. Krabbe Disease Treatment Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy
  • 11.4. Specialty Pharmacy
    • 11.4.1. Independent Specialty Pharmacies
    • 11.4.2. Managed Specialty Pharmacies

12. Krabbe Disease Treatment Market, by End User

  • 12.1. Clinics
    • 12.1.1. Multispecialty Clinics
    • 12.1.2. Specialty Clinics
  • 12.2. Home Care Providers
    • 12.2.1. Licensed Nursing Agencies
    • 12.2.2. Patient's Home
  • 12.3. Hospitals
    • 12.3.1. Children's Hospitals
    • 12.3.2. General Hospitals

13. Krabbe Disease Treatment Market, by Patient Age Group

  • 13.1. Infantile
    • 13.1.1. Symptomatic
  • 13.2. Late Onset
    • 13.2.1. Adolescent
    • 13.2.2. Adult
  • 13.3. Neonatal
    • 13.3.1. Early Diagnosis
    • 13.3.2. Pre Symptomatic

14. Krabbe Disease Treatment Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Krabbe Disease Treatment Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Krabbe Disease Treatment Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Passage Bio, Inc.
    • 17.3.2. Bluebird Bio, Inc.
    • 17.3.3. Genethon
    • 17.3.4. Forge Biologics
    • 17.3.5. Polaryx Therapeutics

LIST OF FIGURES

  • FIGURE 1. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY THERAPY TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS KRABBE DISEASE TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA KRABBE DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA KRABBE DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA KRABBE DISEASE TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE KRABBE DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST KRABBE DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA KRABBE DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC KRABBE DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN KRABBE DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC KRABBE DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION KRABBE DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS KRABBE DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 KRABBE DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO KRABBE DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. KRABBE DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. KRABBE DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. KRABBE DISEASE TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY AAV VECTOR, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY AAV VECTOR, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY AAV VECTOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY AAV VECTOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY AAV VECTOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY AAV VECTOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY AAV VECTOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY AAV VECTOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY AAV2, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY AAV2, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY AAV2, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY AAV2, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY AAV2, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY AAV2, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY AAV9, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY AAV9, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY AAV9, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY AAV9, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY AAV9, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY AAV9, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY LENTIVIRAL VECTOR, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY LENTIVIRAL VECTOR, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY LENTIVIRAL VECTOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY LENTIVIRAL VECTOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY LENTIVIRAL VECTOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY LENTIVIRAL VECTOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY LENTIVIRAL VECTOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY LENTIVIRAL VECTOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY SECOND GENERATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY SECOND GENERATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY SECOND GENERATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY SECOND GENERATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY SECOND GENERATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY SECOND GENERATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY THIRD GENERATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY THIRD GENERATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY THIRD GENERATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY THIRD GENERATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY THIRD GENERATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY THIRD GENERATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY ALLOGENEIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY ALLOGENEIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY ALLOGENEIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY ALLOGENEIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY ALLOGENEIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY ALLOGENEIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY AUTOLOGOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY AUTOLOGOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY AUTOLOGOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY AUTOLOGOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY AUTOLOGOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY AUTOLOGOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY INTRATHECAL, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY INTRATHECAL, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY INTRATHECAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY INTRATHECAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY INTRATHECAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY INTRATHECAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY INTRATHECAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY INTRATHECAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY INTRACEREBROVENTRICULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY INTRACEREBROVENTRICULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY INTRACEREBROVENTRICULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY INTRACEREBROVENTRICULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY INTRACEREBROVENTRICULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY INTRACEREBROVENTRICULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY LUMBAR PUNCTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY LUMBAR PUNCTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY LUMBAR PUNCTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY LUMBAR PUNCTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY LUMBAR PUNCTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY LUMBAR PUNCTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY INTRAVENOUS, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY CENTRAL VENOUS CATHETER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY CENTRAL VENOUS CATHETER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY CENTRAL VENOUS CATHETER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY CENTRAL VENOUS CATHETER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY CENTRAL VENOUS CATHETER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY CENTRAL VENOUS CATHETER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY PERIPHERAL VEIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY PERIPHERAL VEIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY PERIPHERAL VEIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY PERIPHERAL VEIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY PERIPHERAL VEIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY PERIPHERAL VEIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY INPATIENT, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY INPATIENT, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY INPATIENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY INPATIENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY INPATIENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY INPATIENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY INPATIENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY INPATIENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY TERTIARY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY TERTIARY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY TERTIARY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY TERTIARY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY TERTIARY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY TERTIARY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY OUTPATIENT, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY OUTPATIENT, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY OUTPATIENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY OUTPATIENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY OUTPATIENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY OUTPATIENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY OUTPATIENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY OUTPATIENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY AMBULATORY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY AMBULATORY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY AMBULATORY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY AMBULATORY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY AMBULATORY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY AMBULATORY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY SPECIALTY PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY SPECIALTY PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY SPECIALTY PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY SPECIALTY PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY SPECIALTY PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY INDEPENDENT SPECIALTY PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY INDEPENDENT SPECIALTY PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY INDEPENDENT SPECIALTY PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY INDEPENDENT SPECIALTY PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY INDEPENDENT SPECIALTY PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY INDEPENDENT SPECIALTY PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY MANAGED SPECIALTY PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY MANAGED SPECIALTY PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY MANAGED SPECIALTY PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY MANAGED SPECIALTY PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY MANAGED SPECIALTY PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY MANAGED SPECIALTY PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY MULTISPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY MULTISPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY MULTISPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY MULTISPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY MULTISPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY MULTISPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY HOME CARE PROVIDERS, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY HOME CARE PROVIDERS, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY HOME CARE PROVIDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY HOME CARE PROVIDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY HOME CARE PROVIDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY HOME CARE PROVIDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY HOME CARE PROVIDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY HOME CARE PROVIDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY LICENSED NURSING AGENCIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY LICENSED NURSING AGENCIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY LICENSED NURSING AGENCIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY LICENSED NURSING AGENCIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY LICENSED NURSING AGENCIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY LICENSED NURSING AGENCIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY PATIENT'S HOME, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY PATIENT'S HOME, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY PATIENT'S HOME, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY PATIENT'S HOME, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY PATIENT'S HOME, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY PATIENT'S HOME, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY CHILDREN'S HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY CHILDREN'S HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY CHILDREN'S HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY CHILDREN'S HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY CHILDREN'S HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY CHILDREN'S HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY GENERAL HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY GENERAL HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY GENERAL HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY GENERAL HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY GENERAL HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY GENERAL HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY INFANTILE, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY INFANTILE, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY INFANTILE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY INFANTILE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY INFANTILE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY INFANTILE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY INFANTILE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY INFANTILE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY SYMPTOMATIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY SYMPTOMATIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY SYMPTOMATIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY SYMPTOMATIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY SYMPTOMATIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY SYMPTOMATIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY LATE ONSET, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY LATE ONSET, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY LATE ONSET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 292. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY LATE ONSET, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY LATE ONSET, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY LATE ONSET, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 295. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY LATE ONSET, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 296. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY LATE ONSET, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 297. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY ADOLESCENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 298. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY ADOLESCENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 299. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY ADOLESCENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 300. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY ADOLESCENT, BY GROUP, 2025-2032 (USD MILLION)

TAB